Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Michael Spinner, MD
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07021989CT.gov ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06563245CT.gov Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | — | Recruiting | — | — | — |
NCT06164275CT.gov Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05711628CT.gov A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT05900765CT.gov A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma | — | Recruiting | — | — | — |
NCT07171827CT.gov Anti-CD30 (Brentuximab Vedotin) With AVD Versus ABVD Chemotherapy Protocol Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT05404945CT.gov Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | — | Active Not Recruiting | — | — | — |
NCT05008224CT.gov Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | — | Completed | — | — | — |
NCT04624984CT.gov PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL | — | Unknown | — | — | — |
NCT03907488CT.gov Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
Show 8 more trialsShow fewer
NCT03331341CT.gov Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03712202CT.gov Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03527628CT.gov OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | — | Unknown | — | — | — |
NCT03226249CT.gov PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT03233347CT.gov Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02661503CT.gov HD21 for Advanced Stages | — | Unknown | — | — | — |
NCT02166463CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01771107CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Classic Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Michael Spinner, MD | P3 | BB · 68 |
| Dacarbazine | City of Hope Medical Center | P3 | BB |
| Vinblastine | University of Washington | P2 | BB |
| Etoposide | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
| Tislelizumab | Children's Cancer Group, China | P3 | BB |
| Gls-010 | Guangzhou Gloria Biosciences Co., Ltd. | P3 | BB |
| Brentuximab Vedotin | National Cancer Institute (NCI) | P3 | BB |
| Isocyclophosphamide | National Cancer Institute (NCI) | P3 | BB |
+42 more in the Classic Hodgkin Lymphoma cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Classic Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-classic-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →